Sign Out
Known hypersensitivity to entacapone or any of the excipients of Comtan.
Liver impairment (see Pharmacokinetics under Actions).
Patients with pheochromocytoma due to the increased risk of hypertensive crisis.
Concomitant use of entacapone and nonselective monoamine oxidase (MAO-A and MAO-B) inhibitors (eg, phenelzine, tranylcypromine) is contraindicated. Similarly, concomitant use of a selective MAO-A inhibitor plus a selective MAO-B inhibitor and entacapone is contraindicated. Entacapone may be used with selegiline (a selective MAO-B inhibitor), but the daily dose of selegiline should not exceed 10 mg (see Interactions).
A previous history of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.
Use in Pregnancy: No overt teratogenic or primary foetotoxic effects were observed in animal studies in which the exposure levels of entacapone were markedly higher than the therapeutic exposure levels.
As there is no experience in pregnant women, entacapone should not be used during pregnancy.
Use in Lactation: In animal studies, entacapone was excreted in milk. The safety of entacapone in infants is unknown. Women should not breastfeed during treatment with entacapone.
